IMEIK Technology Development Co., Ltd. Class A

IMEIK Technology Development Co., Ltd. Class A

SSZSE:300896
85.80
CNY
+0.41
(+0.48%)
3.30EPS
28.95P/E
28.75BMarket Cap
Mar 10Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.33
0.49
0.65
0.98
1.42
2.46
5.2
4.78
6.4
9.5
10.05
8.13
7.74
Basic EPS, GAAP
0.13
0.08
0.25
0.36
0.54
1.35
3.22
3.16
4.17
6.15
6.5
4.28
3.28
Free Cash Flow per Basic Share
0.1
0.16
- -
0.18
0.43
1.22
2.88
3.04
3.43
6.26
5.6
3.82
- -
Dividend per Share
- -
- -
- -
0.09
0.22
0.2
- -
1.39
1.5
3.32
1.66
5.05
1.03
Book Value per Share
0.39
0.67
1.16
1.43
1.76
2.91
14.97
16.6
19.3
20.96
25.77
25.06
25.92
Tangible Book Value per Share
0.35
0.63
1.11
1.39
1.72
2.86
14.93
16.56
18.11
19.77
24.48
18.42
19.17
Basic Weighted Avg Shares
227
227
217
228
226
227
137
303
303
302
301
302
301
Sales/Revenue/Turnover
75
112
141
222
321
558
709
1,448
1,939
2,869
3,026
2,453
2,332
Operating Margin (%)
43.88
23.43
42.02
41.63
44.2
61.33
66.68
71.24
71.34
72.66
71.32
55.71
45.68
Depreciation Expense
1
1
1
3
8
10
11
19
26
44
45
61
- -
Net Income, GAAP
28
18
53
82
123
306
440
958
1,264
1,858
1,958
1,291
989
Effective Tax Rate (%)
17.17
36.42
16.29
18.11
18.9
15.06
13.78
14.65
14.83
13.95
14.23
13.93
14.85
Profit Margin (%)
37.83
15.79
37.93
36.94
38.27
54.78
62
66.16
65.17
64.77
64.7
52.64
42.41
Working Capital
72
127
172
196
252
497
4,285
3,625
3,910
3,954
4,701
3,498
4,229
LT Debt
- -
- -
- -
6
- -
- -
39
40
48
37
26
10
4
Total Equity
88
152
265
328
405
663
4,531
5,030
5,946
6,485
7,950
8,165
8,502
Return on Invested Capital (%)
- -
13.82
24.28
25.2
31.17
54.98
16.45
19.8
22.77
29.47
26.93
15.84
11.99
Return on Capital (%)
- -
14.73
25.59
29.21
35.2
58.66
17.05
19.91
22.78
29.72
26.99
15.68
11.93
Return on Common Equity (%)
- -
14.73
25.75
27.96
33.96
57.79
16.94
20.03
23.24
30.48
27.68
16.79
12.93

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
243
241
28
LT Borrowings
- -
- -
- -
LT Finance Leases
8
7
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
303
303
303
Market Capitalization
35,476
26,386
28,746

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,243
4,476
4,655
Cash, Cash Equivalents & STI
3,944
3,907
3,612
Accounts Receivable, Net
99
86
81
Inventories
97
103
125
Total Current Liabilities
589
588
426
Payables & Accruals
- -
- -
- -
ST Debt
243
241
28
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
83.31%
12.71%
2.7%
Free Cash Flow
662.59%
37.25%
-31.66%
Net Income, GAAP
66.66%
33.62%
-34.05%
Sales/Revenue/Turnover
40.17%
34.51%
-18.94%
Total Cash Common Dividend
- -
- -
204.61%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
808
849
719
650
3,026
2025
663
636
- -
588
2,453
2026
634
582
528
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.75
1.97
1.54
1.23
6.5
2025
1.47
1.15
- -
0.66
4.28
2026
0.99
0.98
0.66
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.66
2025
- -
- -
- -
0.03
5.05
2026
- -
- -
1
- -
- -

Company Description

CEO
Yi Feng Shi
Full Time Employees
1,458
Sector
Process industries
Industry
Chemicals: specialty
Address
Shimao Building Beijing BE China 100022
IPO Date
Sep 28, 2020
Website
imeik.com
Business
Imeik Technology Development Co., Ltd. (300896.SZ) engages in the research, development, production and sales of biomedical soft tissue repair materials principally for aesthetic medicine applications in China. The company offers a broad portfolio of aesthetic products including cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere, polylactic acid-based dermal fillers, poly-p-dioxanone facial implant threads, medical sodium hyaluronate-hydroxypropyl methylcellulose gel, sodium hyaluronate composite solution for injection, modified sodium hyaluronate gel for injection, and medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; it also provides skin care products targeting the broader health and beauty sectors. Founded in 2004 and headquartered in Beijing, China, Imeik operates primarily in the domestic market with expanding international presence through strategic initiatives. In recent developments, the company plans to acquire an 85% stake in South Korea's REGEN Biotech for approximately USD190 million via a joint venture with an investment fund, aiming to integrate Regen's research, production and sales capabilities as its global business platform; it additionally allocates around CNY1 billion for potential acquisitions over the next two years and pursues partnerships with leading academic institutions to enhance innovation.